Targets › ALB
8 programs from 8 companies in 10 trials: 5 Phase 3, 4 Phase 2, 1 Phase 4; Gastroenterology, Metabolic and endocrine, Oncology; next expected readout Dec 2026.
Binds water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs (Probable). Its main function is the regulation of the colloidal osmotic pressure of blood (Probable). (UniProt, P02768)
Open in Phaseline: the race on ALB, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Cheng Qi | Rice-derived recombinant human serum albumin (OsrHSA) Recombinant human serum albumin produced in rice plants | ALB | Phase 4 | Post-hepatectomy Hypoalbuminemia | Jul 2027 |
| Democritus University of Thrace | Human albumin Intravascular volume expander to prevent reflex renal vasoconstriction during diuresis | ALB | Phase 3 | Diuretics Drug Reactions | Dec 2026 |
| AstraZeneca | CAEL-101 monoclonal antibody against misfolded light chain amyloid deposits | ALB | Phase 3 | AL Amyloidosis | Apr 2027 |
| Capital Medical University | 25% human albumin Plasma volume expansion and neuroprotection in acute ischemic stroke | ALB | Phase 3 | Acute Ischemic Stroke | Jun 2027 |
| Aleksander Krag | Human albumin Human serum albumin protein replacement therapy | ALB | Phase 3 | Decompensated Cirrhosis and Ascites | – |
| Hunter Holmes Mcguire Veteran Affairs Medical Center | Albumin Infusion (Albutein) Intravenous human serum albumin | ALB | Phase 2 | Cirrhosis | Dec 2026 |
| Anahita Rabiee MD MHS | Albumin infusion (25% albumin) Osmotic diuretic and oncotic pressure modulator | ALB | Phase 2 | Cirrhosis | Dec 2026 |
| The First Hospital of Jilin University | Human Serum Albumin Infusion (LAT Group) Albumin replacement therapy - maintaining serum albumin levels above 25 g/L | ALB | Phase 2 | Postoperative Hypoalbuminemia | – |
AL Amyloidosis (2) Postoperative Hypoalbuminemia (2) Cirrhosis (2) Post-hepatectomy Hypoalbuminemia (1) Diuretics Drug Reactions (1) Acute Ischemic Stroke (1) Decompensated Cirrhosis and Ascites (1)
protein or peptide (6), small molecule (1), mixed (1)
AstraZeneca (1) Cheng Qi (1) The First Hospital of Jilin University (1) Democritus University of Thrace (1) Hunter Holmes Mcguire Veteran Affairs Medical Center (1) Capital Medical University (1) Aleksander Krag (1) Anahita Rabiee MD MHS (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.